◎ Sugi Atlas

Atlas / Disease / Peptic ulcer disease

Peptic ulcer disease

disease
On this page

Also known as acute peptic ulcer with haemorrhageacute peptic ulcer with haemorrhage and perforationacute peptic ulcer without haemorrhage and without perforationpeptic ulcer

Summary

Peptic ulcer disease (MONDO:0004247) is a disease (an umbrella term covering 6 Mondo subtypes) with 3 cohort genes (183 GWAS associations across 36 studies) and 85 clinical trials. Top therapeutic interventions include clarithromycin, esomeprazole, and lansoprazole.

At a glance

  • Umbrella term: 6 Mondo subtypes
  • Cohort genes: 3
  • GWAS associations: 183
  • Clinical trials: 85

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepeptic ulcer disease
Mondo IDMONDO:0004247
MeSHD010437
DOIDDOID:750
NCITC3318
SNOMED CT13200003
UMLSC0030920
MedGen45384
Is cancer (heuristic)no

Also known as: acute peptic ulcer with haemorrhage · acute peptic ulcer with haemorrhage and perforation · acute peptic ulcer without haemorrhage and without perforation · peptic ulcer

Data availability: 183 GWAS associations (36 studies).

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › peptic ulcer disease

Related subtypes (30): benign digestive system neoplasm, autoimmune disorder of gastrointestinal tract, gastrointestinal mucositis, diarrheal disease, pancreas disorder, hepatobiliary disorder, digestive system cancer, stomach disorder, intestinal disorder, Meckel diverticulum, Cronkhite-Canada syndrome, diverticulosis, small-intestinal, diverticulosis of bowel, hernia, and retinal detachment, congenital enteropathy due to enteropeptidase deficiency, hereditary mixed polyposis syndrome, caudal duplication, Moyamoya disease with early-onset achalasia, hyperplastic polyposis syndrome, thoraco-abdominal enteric duplication, digestive duplication, juvenile polyposis syndrome, umbilical cord ulceration-intestinal atresia syndrome, growth retardation-mild developmental delay-chronic hepatitis syndrome, common mesentery, neoplasm of oropharynx, gastrointestinal polyp, digestive system neuroendocrine neoplasm, digestive system infectious disorder, upper digestive tract disorder, congenital peritoneal encapsulation

Subtypes (6): gastric ulcer, gastrojejunal ulcer, active peptic ulcer disease, peptic ulcer perforation, duodenal ulcer, peptic esophagitis

Genetics & variants

GWAS landscape

183 GWAS associations across 36 studies. Top hits map to 24 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs29202934e-126PSCA - LY6KG0.2
rs22940081e-123JRK, PSCAT0.22
rs105006618e-27CNGA4 - CCKBRC0.1
rs38054975e-25TTC33T0.08
rs81767196e-24ABOTC0.07
rs340744111e-22EIF1 - GASTT0.07
rs95819572e-20URADT0.07
rs68603284e-20TTC33C0.08
rs1154787356e-18ABOA0.13
rs5876119534e-17ABOC0.15
rs116656741e-15SEC1P - FUT2G0.09
rs4926021e-15FUT2A0.08
rs6813432e-15FUT2C0.92
rs726077444e-15SND1A0.15
rs29763882e-14PSCA, JRKG1.09
rs61238372e-14GNASA0.05
rs7491613123e-14PDX1CCCCTCCTCT0.08
rs29202791e-13PSCA, JRKA0.1
rs2009643e-13RNU7-26P - OR2B2G1.05
chr19:492069853e-13G0.15
rs5162465e-13FUT2?
rs81146896e-13GNASA0.07
chr17:398576191e-12A0.17
rs9678232e-12CA10 - LINC01982A0.96
rs114162482e-12GGT1CT0.08
rs13458949813e-12MUC1T0.14
rs116920853e-12NHEJ1T0.05
rs129992573e-12LINC01940 - HDAC4?
rs37711823e-12IL1RL2?1.01
rs5295654e-12ABO?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90570613You D2025121,9401,693,792A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST011500Wu Y202190,175366,152GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression.
GCST90134604Adewuyi EO202271,880823,039A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer’s disease and gastrointestinal tract disorders.
GCST90134605Adewuyi EO202271,880749,530A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer’s disease and gastrointestinal tract disorders.
GCST90570625You D202558,5591,377,019A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90570635You D202558,174758,764A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90270926He Y202329,739240,675East Asian-specific and cross-ancestry genome-wide meta-analyses provide mechanistic insights into peptic ulcer disease.
GCST90270930He Y202329,739240,675East Asian-specific and cross-ancestry genome-wide meta-analyses provide mechanistic insights into peptic ulcer disease.
GCST90570629You D202529,266496,111A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases.
GCST90454171Jiang M202324,906731,917Genetic and observational associations of lung function with gastrointestinal tract diseases: pleiotropic and mendelian randomization analysis.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding3
Tier 2: splice/UTR4
Tier 3: regulatory1
Tier 4: intronic/intergenic42

MAF distribution

BucketVariants
common (>=0.05)48
low_freq (0.01-0.05)2
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant24
intergenic_variant9
unknown5
synonymous_variant4
5_prime_UTR_variant2
stop_gained2
3_prime_UTR_variant2
frameshift_variant1
regulatory_region_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs29202938142683996C>A,G,T0.392intergenic_variantPSCA - LY6K4e-126Tier 4: intronic/intergenic
rs22940088142680513C>T0.3655_prime_UTR_variantJRK, PSCA1e-123Tier 2: splice/UTR
rs10500661116252514T>C0.162intergenic_variantCNGA4 - CCKBR8e-27Tier 4: intronic/intergenic
rs3805497540746783A>C,G,T0.467intron_variantTTC335e-25Tier 4: intronic/intergenic
rs81767199133257522T>TC0.415frameshift_variantABO6e-24Tier 1: coding
rs340744111741710996C>T0.465regulatory_region_variantEIF1 - GAST1e-22Tier 3: regulatory
rs95819571327983752C>T0.264intron_variantURAD2e-20Tier 4: intronic/intergenic
rs6860328540729872T>C0.423intron_variantTTC334e-20Tier 4: intronic/intergenic
rs1154787359133274295A>T0.159intron_variantABO6e-18Tier 4: intronic/intergenic
rs5876119539133270004C>A,G0.18intron_variantABO4e-17Tier 4: intronic/intergenic
rs116656741948693018A>G,T0.447intergenic_variantSEC1P - FUT21e-15Tier 4: intronic/intergenic
rs4926021948703160A>C,G,T0.478synonymous_variantFUT21e-15Tier 4: intronic/intergenic
rs6813431948703205C>A,T0.49stop_gainedFUT22e-15Tier 1: coding
rs726077447127920488G>A0.095intron_variantSND14e-15Tier 4: intronic/intergenic
rs29763888142678838G>A0.42intergenic_variantPSCA, JRK2e-14Tier 4: intronic/intergenic
rs61238372058890516G>A0.479synonymous_variantGNAS2e-14Tier 4: intronic/intergenic
rs74916131213279254470.4063_prime_UTR_variantPDX13e-14Tier 2: splice/UTR
rs29202798142680717A>C,G,T0.446intron_variantPSCA, JRK1e-13Tier 4: intronic/intergenic
rs200964627899165G>C0.19intergenic_variantRNU7-26P - OR2B23e-13Tier 4: intronic/intergenic
chr19:492069850.4973e-13Tier 4: intronic/intergenic
rs5162461948702915C>A,G,T0.05intron_variantFUT25e-13Tier 4: intronic/intergenic
rs81146892058901835G>A,C0.407intron_variantGNAS6e-13Tier 4: intronic/intergenic
chr17:398576190.2521e-12Tier 4: intronic/intergenic
rs9678231752239916A>G0.39intergenic_variantCA10 - LINC019822e-12Tier 4: intronic/intergenic
rs114162482224612511C>CT0.321intron_variantGGT12e-12Tier 4: intronic/intergenic
rs134589498111551920030.048synonymous_variantMUC13e-12Tier 4: intronic/intergenic
rs116920852219098828C>G,T0.461intron_variantNHEJ13e-12Tier 4: intronic/intergenic
rs129992572238947706G>C0.05intergenic_variantLINC01940 - HDAC43e-12Tier 4: intronic/intergenic
rs37711822102228167T>C0.05intron_variantIL1RL23e-12Tier 4: intronic/intergenic
rs5295659133274084C>A,G,T0.05intron_variantABO4e-12Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TRAF3Orphanet:1930Herpes simplex virus encephalitis
CNTNAP2Orphanet:163681CNTNAP2-related developmental and epileptic encephalopathy
DEPDC5Orphanet:442835Non-specific early-onset epileptic encephalopathy
DEPDC5Orphanet:98784Sleep-related hypermotor epilepsy
DEPDC5Orphanet:98820Familial focal epilepsy with variable foci

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only3

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TRAF3HGNC:12033ENSG00000131323Q13114TNF receptor-associated factor 3gwas
CNTNAP2HGNC:13830ENSG00000174469Q9UHC6Contactin-associated protein-like 2gwas
DEPDC5HGNC:18423ENSG00000100150O75140GATOR1 complex protein DEPDC5gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TRAF3TNF receptor-associated factor 3Cytoplasmic E3 ubiquitin ligase that regulates various signaling pathways, such as the NF-kappa-B, mitogen-activated protein kinase (MAPK) and interferon regulatory factor (IRF) pathways, and thus controls a lot of biological processes in…
CNTNAP2Contactin-associated protein-like 2Required for gap junction formation.
DEPDC5GATOR1 complex protein DEPDC5As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor12.8×0.587
Other/Unknown21.2×0.587

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TRAF3Transcription factornoZnf_TRAF, Znf_RING, MATH/TRAF_dom
CNTNAP2Other/UnknownnoFA58C, EGF, Laminin_G
DEPDC5Other/UnknownnoDEP_dom, IML1, WH-like_DNA-bd_sf

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)3
unknown0

Top tissues across cohort

TissueCohort genes
cartilage tissue1
monocyte1
mononuclear cell1
C1 segment of cervical spinal cord1
corpus callosum1
superior frontal gyrus1
frontal pole1
middle frontal gyrus1
paraflocculus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TRAF3258ubiquitousmarkercartilage tissue, monocyte, mononuclear cell
CNTNAP2127broadmarkercorpus callosum, superior frontal gyrus, C1 segment of cervical spinal cord
DEPDC5236ubiquitousmarkerparaflocculus, frontal pole, middle frontal gyrus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TRAF33,493
CNTNAP22,097
DEPDC51,273

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
DEPDC5O7514011
TRAF3Q1311410
CNTNAP2Q9UHC61

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
TRAF3 deficiency - HSE11903.3×0.006TRAF3
Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation1475.8×0.006TRAF3
TICAM1-dependent activation of IRF3/IRF71407.9×0.006TRAF3
TRAF3-dependent IRF activation pathway1380.7×0.006TRAF3
Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF71380.7×0.006TRAF3
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway1335.9×0.006TRAF3
Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)1300.5×0.006TRAF3
Negative regulators of DDX58/IFIH1 signaling1163.1×0.010TRAF3
Ovarian tumor domain proteases1139.3×0.010TRAF3
SARS-CoV-1 activates/modulates innate immune responses1135.9×0.010TRAF3
Amino acids regulate mTORC11100.2×0.012DEPDC5
TNFR2 non-canonical NF-kB pathway190.6×0.012TRAF3
SARS-CoV-2 activates/modulates innate and adaptive immune responses144.6×0.022TRAF3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
limbic system development12808.7×0.006CNTNAP2
superior temporal gyrus development12808.7×0.006CNTNAP2
clustering of voltage-gated potassium channels11404.3×0.006CNTNAP2
protein localization to juxtaparanode region of axon11404.3×0.006CNTNAP2
neuron recognition11123.5×0.006CNTNAP2
regulation of interferon-beta production11123.5×0.006TRAF3
Toll signaling pathway1802.5×0.006TRAF3
positive regulation of gap junction assembly1802.5×0.006CNTNAP2
vocal learning1702.2×0.006CNTNAP2
regulation of defense response to virus1702.2×0.006TRAF3
TRIF-dependent toll-like receptor signaling pathway1510.7×0.008TRAF3
thalamus development1468.1×0.008CNTNAP2
regulation of proteolysis1432.1×0.008TRAF3
striatum development1374.5×0.008CNTNAP2
prepulse inhibition1374.5×0.008CNTNAP2
vocalization behavior1295.6×0.009CNTNAP2
transmission of nerve impulse1216.1×0.012CNTNAP2
toll-like receptor signaling pathway1200.6×0.012TRAF3
toll-like receptor 4 signaling pathway1175.5×0.013TRAF3
regulation of canonical NF-kappaB signal transduction1160.5×0.013TRAF3
adult behavior1156.0×0.013CNTNAP2
positive regulation of type I interferon production1140.4×0.014TRAF3
obsolete negative regulation of NF-kappaB transcription factor activity1119.5×0.015TRAF3
type I interferon-mediated signaling pathway1114.6×0.015TRAF3
tumor necrosis factor-mediated signaling pathway1110.1×0.015TRAF3
negative regulation of TORC1 signaling1108.0×0.015DEPDC5
cellular response to amino acid starvation1106.0×0.015DEPDC5
learning193.6×0.016CNTNAP2
neuron projection morphogenesis192.1×0.016CNTNAP2
social behavior190.6×0.016CNTNAP2

Therapeutics

Drugs indicated for this disease

20 approved, 14 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Bismuth Subcitrate PotassiumApproved (phase 4)
CarbenoxoloneApproved (phase 4)
CelecoxibApproved (phase 4)
CimetidineApproved (phase 4)
Cortisone AcetateApproved (phase 4)
DexamethasoneApproved (phase 4)
DexlansoprazoleApproved (phase 4)
FamotidineApproved (phase 4)
LansoprazoleApproved (phase 4)
MisoprostolApproved (phase 4)
NizatidineApproved (phase 4)
OmeprazoleApproved (phase 4)
PirenzepineApproved (phase 4)
PrednisoloneApproved (phase 4)
PrednisoneApproved (phase 4)
ProglumideApproved (phase 4)
RabeprazoleApproved (phase 4)
RanitidineApproved (phase 4)
SucralfateApproved (phase 4)
VonoprazanApproved (phase 4)
AbeprazanPhase 3 (in late-stage trials)
Alginic AcidPhase 3 (in late-stage trials)
AspirinPhase 3 (in late-stage trials)
DiosminPhase 3 (in late-stage trials)
EsomeprazolePhase 3 (in late-stage trials)
GefarnatePhase 3 (in late-stage trials)
IbuprofenPhase 3 (in late-stage trials)
IlaprazolePhase 3 (in late-stage trials)
LafutidinePhase 3 (in late-stage trials)
NaproxenPhase 3 (in late-stage trials)
PantoprazolePhase 3 (in late-stage trials)
RebamipidePhase 3 (in late-stage trials)
TegoprazanPhase 3 (in late-stage trials)
TeprenonePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Somatostatin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3

Druggability breadth: 0 of 3 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TRAF300
CNTNAP200
DEPDC500

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug3TRAF3, CNTNAP2, DEPDC5

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TRAF30—
CNTNAP20—
DEPDC50—

Clinical trials & evidence

Clinical trials

Clinical trials: 85.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified41
PHASE424
PHASE311
PHASE14
PHASE23
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07139366PHASE4RECRUITINGSaccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
NCT07537634PHASE4RECRUITINGVonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
NCT00137033PHASE4COMPLETEDCelebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
NCT00164866PHASE4COMPLETEDAdministration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
NCT00247130PHASE4WITHDRAWNComparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer
NCT00471029PHASE4UNKNOWNCompare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
NCT00534443PHASE4COMPLETEDImportance of Cytokines in Peptic Ulcer Disease: Implications for Treatment
NCT00843063PHASE4COMPLETEDFamotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion
NCT00881413PHASE4WITHDRAWNEsomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding
NCT01180179PHASE4COMPLETEDPPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers
NCT01353144PHASE4COMPLETEDA Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
NCT01453036PHASE4COMPLETEDClarithromycin Resistant Tailored Therapy
NCT01667575PHASE4COMPLETEDEfficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
NCT01667692PHASE4COMPLETEDAizthromycin or Clarithromycin in H-pylori Eradication Regimen
NCT01667718PHASE4COMPLETEDBismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
NCT02175901PHASE4COMPLETEDAmoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication
NCT02296021PHASE4COMPLETEDHelicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
NCT02536989PHASE4COMPLETEDDifferent Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
NCT02633930PHASE4COMPLETEDHelicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy
NCT02648659PHASE4COMPLETEDThe Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients
NCT04678492PHASE4COMPLETEDHelicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT05237115PHASE4COMPLETEDHelicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05742568PHASE4COMPLETEDEffects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT07312721PHASE4COMPLETEDComparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis
NCT06284876PHASE3RECRUITINGStudy to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
NCT06439563PHASE3RECRUITINGStudy to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
NCT00161096PHASE3UNKNOWNOn-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
NCT00175032PHASE3COMPLETEDA Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
NCT00261300PHASE3COMPLETEDLong-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
NCT00374101PHASE3COMPLETEDHigh Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding
NCT00450658PHASE3COMPLETEDEfficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
NCT01142245PHASE3COMPLETEDEffect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
NCT01182597PHASE3UNKNOWNOral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis
NCT01828645PHASE2/PHASE3COMPLETEDResidual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein
NCT02084420PHASE3COMPLETEDEfficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment
NCT04140591PHASE2/PHASE3TERMINATEDProton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis
NCT04784910PHASE3COMPLETEDStudy to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
NCT00152399PHASE2COMPLETEDStudy to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
NCT01138969PHASE2COMPLETEDEfficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
NCT02342470PHASE2COMPLETEDEfficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CLARITHROMYCIN47
ESOMEPRAZOLE47
LANSOPRAZOLE47
AMOXICILLIN46
BERBERINE46
PANTOPRAZOLE45
OMEPRAZOLE44
PROPRANOLOL43
CELECOXIB42
FURAZOLIDONE42
METRONIDAZOLE42
NAPROXEN42
TETRACYCLINE42
ASPIRIN41
AZITHROMYCIN41
FAMOTIDINE41
RANITIDINE41
ILAPRAZOLE33
ABEPRAZAN31
BLOOD, WHOLE31
LAFUTIDINE31
DEXPROPRANOLOL21
AGN-20190411
IRSOGLADINE MALEATE11
CHEMBL313767309
CHEMBL161825402
CHEMBL137473802
CHEMBL157216702
CHEMBL528266901
CHEMBL429938101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 66

This page pulls from 66 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot